Literature DB >> 35241887

In situ cryoablation of sacral Giant Cell Tumor using three-dimensional (3D) model: A case report.

Avital Elias1, Amit Benady1,2, Eran Golden2, Ortal Segal1,3, Solomon Dadia1,2,3.   

Abstract

Three-dimensional planning of in-situ (trans-sacral) image guided cryoablation provides a method to treat sacral GCTs that accommodates the intricacies of the pelvis offering a safer, more efficacious alternative. Here we report on IM a 23-year-old female with a sacral GCT. She presented to Tel Aviv Medical Center with ongoing pain as well as neurological symptoms. For six years, the patient was in-and-out of the hospital for Denosumab treatment and recurrent infections. Eventually, further treatment became necessary, and she was treated with image guided cryoablation. By six months follow-up, the patient was mobile and pain-free.
© 2022 Professor P K Surendran Memorial Education Foundation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2D, Two-Dimensional; 3- dimensional printing; 3D, Three-Dimensional; CAD, Computer-Aided Design; CT, Computed Tomography; Case report; GCT, Giant Cell Tumor; Giant cell tumor; Orthopedic oncology; PSI, Patient Specific Instrument; Pelvis; RFA, Radio Frequency Ablation; STL, Standard Triangle Language

Year:  2022        PMID: 35241887      PMCID: PMC8857548          DOI: 10.1016/j.jor.2022.02.007

Source DB:  PubMed          Journal:  J Orthop        ISSN: 0972-978X


  12 in total

Review 1.  Percutaneous ablation for bone and soft tissue metastases--why cryoablation?

Authors:  Matthew R Callstrom; A Nick Kurup
Journal:  Skeletal Radiol       Date:  2009-09       Impact factor: 2.199

2.  Percutaneous CT-Guided Cryoablation as an Alternative Treatment for an Extensive Pelvic Bone Giant Cell Tumor.

Authors:  Pedro Sergio Brito Panizza; Conrado Furtado de Albuquerque Cavalcanti; Nise Hitomi Yamaguchi; Claudia Costa Leite; Giovanni Guido Cerri; Marcos Roberto de Menezes
Journal:  Cardiovasc Intervent Radiol       Date:  2015-07-01       Impact factor: 2.740

3.  Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?

Authors:  Andrea Sambri; Manuel R Medellin; Costantino Errani; Laura Campanacci; Tomohiro Fujiwara; Davide Donati; Michael Parry; Robert Grimer
Journal:  J Orthop Sci       Date:  2019-05-30       Impact factor: 1.601

Review 4.  Current treatment of sacral giant cell tumour of bone: a review.

Authors:  C C Shen; H Li; Z L Shi; H M Tao; Z M Yang
Journal:  J Int Med Res       Date:  2012       Impact factor: 1.671

Review 5.  The current standing on the use of denosumab in giant cell tumour of the bone.

Authors:  Vivek Ajit Singh; Ajay Puri
Journal:  J Orthop Surg (Hong Kong)       Date:  2020 Sep-Dec       Impact factor: 1.118

6.  Computer-Based Vertebral Tumor Cryoablation Planning and Procedure Simulation Involving Two Cases Using MRI-Visible 3D Printing and Advanced Visualization.

Authors:  Jeffrey P Guenette; Nathan Himes; Andreas A Giannopoulos; Tatiana Kelil; Dimitris Mitsouras; Thomas C Lee
Journal:  AJR Am J Roentgenol       Date:  2016-08-09       Impact factor: 3.959

Review 7.  Diagnosis and management of sacral tumors.

Authors:  Daniel M Sciubba; Rory J Petteys; Giannina L Garces-Ambrossi; Joseph C Noggle; Matthew J McGirt; Jean-Paul Wolinsky; Timothy F Witham; Ziya L Gokaslan
Journal:  J Neurosurg Spine       Date:  2009-03

8.  Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.

Authors:  Daniel A Müller; Giovanni Beltrami; Guido Scoccianti; Domenico A Campanacci; Alessandro Franchi; Rodolfo Capanna
Journal:  World J Surg Oncol       Date:  2016-11-04       Impact factor: 2.754

9.  Rare Treatment for a Rare Tumor: Cryoablation of a Granular Cell Tumor.

Authors:  Lauren Derstine; Erik Soule; Naudare Shabandi; Zarina Arutyunova; Chandana Lall; Christopher Scuderi; Jerry Matteo
Journal:  Gastrointest Tumors       Date:  2019-12-18

10.  Huge giant cell tumor of the sacrum: A case report.

Authors:  Li-Feng Qin; Dan Peng; Li-Hua Qin; Min Xu; Han Fang; Qing Zhang
Journal:  Oncol Lett       Date:  2014-01-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.